Ajanta Pharma Limited provided revenue guidance for the fiscal year 2025. For the year, the company expects overall revenue to grow in low teens for the Fiscal Year 2025, though Branded Generics will grow in mid-teens.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2,267 INR | +2.11% |
|
-0.90% | +8.78% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+8.78% | 3.32B | |
+24.53% | 44.76B | |
+30.99% | 23.16B | |
+24.13% | 16.02B | |
+21.15% | 14.32B | |
+68.67% | 13.7B | |
-0.05% | 6.79B | |
-13.29% | 6.47B | |
-8.87% | 5.73B | |
+13.53% | 5.65B |
- Stock Market
- Equities
- AJANTPHARM Stock
- News Ajanta Pharma Limited
- Ajanta Pharma Limited Provides Revenue Guidance for the Fiscal Year 2025